- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01694784
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
Most prevention efforts focus on promoting services (e.g. vaccination, screening tests). While some of these services have clear net benefit, many instead have possible or clear net harm. Currently, three quarters of services graded by the U.S. Preventive Services Task Force (USPSTF) have possible or clear net harm (C, I, and D services). Many of these services are delivered in healthcare settings at higher rates than what might be expected based on their potential for harm. This leads to adverse outcomes, excess costs, and missed opportunities to deliver more quality care. An important issue in delivering prevention messages is how to shift toward a focus on the appropriateness of prevention: encouraging services with clear net benefit and either discouraging or reducing demand for services with possible or clear net harm. Unfortunately, little is known about what drives overuse of potentially harmful screening services or how to make harms relevant to patients.
This randomized controlled trial (RCT) of 775 patients at 4 primary care practices aims to 1) assess factors associated with intent to receive possibly or clearly harmful screening services and 2) determine whether and how patients' plans to get screened change with various presentations of information about harms (e.g. qualitative, quantitative, narrative, framed). The investigators will focus on three types of screening services: osteoporosis screening (previous C recommendation and now no recommendation for women < 65 years old with no fracture risk factors), prostate-specific antigen (PSA) screening (D recommendation for all men, regardless of age), and colorectal cancer (CRC) screening (C for ages 76-85).
Panoramica dello studio
Stato
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27704
- Duke Primary Care Research Consortium
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Women between ages 50 to 85
- Men between ages 50 to 85
- Eligible for exemplar service of interest (see below for specifics of inclusion/exclusion for specific services)
Exclusion Criteria:
- Current treatment of psychosis
- History of alcohol or substance abuse within the last 2 years
- Dementia or other severe cognitive dysfunction
- serious medical illnesses with a life expectancy of less than 2 years (e.g., metastatic cancer)
- inability to speak and understand English
- blindness
- presentation for an acute medical visit
- no telephone number
Osteoporosis Screening (women aged 50-64)
Exclusion Criteria:
- a personal history of osteoporosis
- a personal history of moderate or severe osteopenia
- BMI (body mass index) < 18.5
- personal history of non-traumatic fracture
- family history of hip fracture
- current smoking
- current use of prednisone (>30 consecutive days)
- alcohol use of 3 or more drinks/day.
Prostate Cancer screening (men aged 50-69)
Exclusion Criteria:
- a prior history of prostate cancer
Colorectal Cancer Screening (men and women aged 76-85)
Exclusion Criteria:
- prior history of colorectal cancer
- adenomatous colon polyps > 6mm (or 2 or more < 6mm)
- symptoms referable to colorectal cancer
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Quantitative
In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet.
Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
|
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed.
In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e.
box containing key facts and rates).
In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision.
As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
|
Comparatore attivo: Qualitative
In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
|
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed.
In the qualitative information sheet, harms will be communicated using verbal descriptors.
In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
|
Sperimentale: Narrative
In the narrative arm, we will present harms using patient narratives (i.e.
descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet.
To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
|
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed.
In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box.
In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
|
Sperimentale: Framed
In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e.
use a gain frame).
In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
|
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed.
In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box.
In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change from Baseline in Intent to Accept Screening Immediately Post-intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Following the example of others, we will measure intent to accept screening services with possible or clear net harm with a single item "I plan to get screened for (name of screening test) in the next year."
Because the recommended screening intervals for services under study are variable and not all participants will be due for screening in the next year, we will additionally query participants about plans for screening within the recommended screening interval (e.g.
osteoporosis screening--5 years; CRC--10 years).
Responses will range from "strongly disagree" to strongly agree".
All outcomes will be measured before and after participants receive the information sheet.
All data will be collected at the one study visit.
|
Pre and Post Intervention (same visit - Day 1)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change from Baseline in Perceived Disease Risk Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Perceived risk or susceptibility of disease will be measured for each disease state under study using one item that reads, "How likely is that you will get (insert prostate cancer, osteoporosis, or colon cancer) in the next 10 years?"
Answers will be on a likert scale from "not at all likely" to "very likely."
|
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in Perceived Disease Severity Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Perceived Disease Severity will be measured for each disease state under study using the Revised Illness Perceptions Questionnaire for Healthy People.
It includes the following four questions: 1) x (insert prostate cancer, osteoporosis, or colon cancer) has serious financial consequences; 2) x strongly affects the way the patient sees himself as a person; 3) x causes difficulties to those close to the patient; 4) x is very serious.
Answers will be on a 5-point scale from "strongly disagree" to "strongly agree."
|
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in Disease Specific Knowledge Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Two questions central to understanding each exemplar service (i.e. prostate cancer screening, osteoporosis screening, colon cancer screening) were selected to assess specific knowledge. Response options include true, false, or don't know. Questions for prostate cancer screening are:
Questions for colon cancer screening are:
Questions for Osteoporosis screening are:
|
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in Disease-Specific Screening Attitudes Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Six questions will assess participants' attitudes about each screening service under study. Questions include:
Response options range from "strongly disagree" to "strongly agree". |
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in Decisional Balance Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Decisional balance will be measured by a single item for each screening service under study.
Participants will be asked, "Which best describes how you feel right now?" Participants will select one of the following answers: 1) The benefits of X (insert prostate cancer, colon cancer, osteoporosis) screening greatly outweigh the harms; 2) The benefits of X screening somewhat outweigh the harms; 3) The benefits and harms of X screening are about the same; 4) The harms of X screening somewhat outweigh the benefits; and 5) The harms of X screening greatly outweigh the benefits.
|
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in Values Clarity Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
Values Clarity will be measured with three items for the values subscale of the decisional conflict scale. Items include:
Response options range from strongly disagree to strongly agree. |
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in General Screening Knowledge Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1)
|
General screening knowledge will be assessed using 8 items developed by investigators. Questions include:
Response options are true, false, or don't know. |
Pre and Post Intervention (same visit - Day 1)
|
Change from Baseline in General Screening Attitudes Immediately Post-Intervention
Lasso di tempo: Pre and Post Intervention (same visit - Day 1))
|
General Screening Attitudes will be assessed at baseline by 38 questions that were developed by investigators and assessed for content validity by panel of experts. Questions assess the following sub-constructs: General approach to screening, Value of Screening, Need to Know about Disease, Early Detection/Treatment, Benefits, Harms, Anticipated Regret in Choosing for/against screening, Duty/Responsibility to be screened, Effect on screening on MD/patient relationship. Response options range from "strongly disagree" to "strongly agree" on a 5-point scale. At post intervention, a subset of 12 of the 38 questions (1-2 from each subconstruct) will be used to assess changes in general screening attitudes. |
Pre and Post Intervention (same visit - Day 1))
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Key moderating variables
Lasso di tempo: pre-intervention
|
Multiple variables will be measured to examine whether they moderate the effect of the intervention on the primary outcome intent for screening. These variables include:
|
pre-intervention
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Stacey Sheridan, MD, University of North Carolina, Chapel Hill
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 12-1338
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro colorettale
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Stati Uniti, Singapore, Canada
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
University of ChicagoNational Cancer Institute (NCI)CompletatoAdenocarcinoma pancreatico | Adenocarcinoma gastrico | Adenocarcinoma pancreatico metastatico | Neoplasia gastrointestinale maligna | Cancro al pancreas in stadio III | Cancro al pancreas in stadio IV | Carcinoma della cistifellea | Cancro alla cistifellea in stadio IV | Cancro gastrico in stadio IV | Cancro... e altre condizioniStati Uniti
Prove cliniche su Quantitative Information Sheet
-
Azienda Ospedaliera Universitaria Integrata VeronaCompletato
-
Matthias LöhrCompletatoEsofago di BarrettSvezia
-
Stanford UniversityBill and Melinda Gates FoundationCompletatoBambino | Gravidanza | Infante | Nutrizione | Salute
-
University Hospital, LilleSconosciutoMalattia di Alzheimer | PATTERN VARIANTE ELETTROENCEFALOGRAFICO 1 (Disturbo)Francia
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)CompletatoCancro al seno | Cancro colorettale | Cancro alla prostata | Cancro toracicoStati Uniti
-
Harvard School of Public Health (HSPH)Bill and Melinda Gates Foundation; St. John's Research Institute; Karnataka Health... e altri collaboratoriCompletatoSepsi | Emorragia postpartum | Asfissia alla nascita | Preeclampsia/Eclampsia | Complicanze ostetriche e perinatali | Travaglio ostruito/prolungato
-
Vidya RamanCompletato
-
The Hospital for Sick ChildrenAttivo, non reclutante
-
Instituto de Investigación Sanitaria AragónCompletato
-
The University of Hong KongHospital Authority, Hong Kong; University Grants Committee, Hong KongReclutamentoInsufficienza respiratoria ipercapnica | Ventilazione non invasivaHong Kong